To include your compound in the COVID-19 Resource Center, submit it here.

Basal insulin peglispro: Phase III data

Top-line data from the 52-week, double-blind, international Phase III IMAGINE-3 trial in 1,114 Type I diabetics showed that once-daily subcutaneous basal insulin peglispro met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 52. Eli Lilly also analyzed

Read the full 452 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers